Solid Biosciences (SLDB) Cash from Financing Activities (2017 - 2024)
Historic Cash from Financing Activities for Solid Biosciences (SLDB) over the last 7 years, with Q4 2024 value amounting to $6.9 million.
- Solid Biosciences' Cash from Financing Activities rose 127425.74% to $6.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $122.4 million, marking a year-over-year increase of 6272.64%. This contributed to the annual value of $122.4 million for FY2024, which is 382174.89% up from last year.
- Per Solid Biosciences' latest filing, its Cash from Financing Activities stood at $6.9 million for Q4 2024, which was up 127425.74% from $3.3 million recorded in Q3 2024.
- Solid Biosciences' Cash from Financing Activities' 5-year high stood at $135.2 million during Q1 2021, with a 5-year trough of -$238000.0 in Q2 2021.
- Moreover, its 4-year median value for Cash from Financing Activities was $505000.0 (2023), whereas its average is $25.6 million.
- The largest annual percentage gain for Solid Biosciences' Cash from Financing Activities in the last 5 years was 11313787.88% (2022), contrasted with its biggest fall of 13333.33% (2022).
- Over the past 4 years, Solid Biosciences' Cash from Financing Activities (Quarter) stood at $66000.0 in 2021, then skyrocketed by 113137.88% to $74.7 million in 2022, then tumbled by 99.32% to $505000.0 in 2023, then skyrocketed by 1274.26% to $6.9 million in 2024.
- Its Cash from Financing Activities stands at $6.9 million for Q4 2024, versus $3.3 million for Q3 2024 and $5.0 million for Q2 2024.